Lantheus Holdings Inc. (LNTH) Shares Up 4.8%
Lantheus Holdings Inc. (NASDAQ:LNTH) shot up 4.8% on Thursday . The stock traded as high as $7.75 and last traded at $7.44, with a volume of 279,427 shares traded. The stock had previously closed at $7.10.
Several brokerages have weighed in on LNTH. Zacks Investment Research raised Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $7.00 price target on the stock in a research report on Monday, August 8th. Jefferies Group restated a “buy” rating on shares of Lantheus Holdings in a research report on Friday, August 5th. Finally, Credit Suisse Group AG set a $4.00 target price on Lantheus Holdings and gave the company a “hold” rating in a research report on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $5.80.
The firm has a market cap of $227.90 million and a PE ratio of 8.47. The company’s 50 day moving average price is $4.85 and its 200-day moving average price is $2.84.
Lantheus Holdings (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, August 4th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.18. The company earned $78 million during the quarter, compared to analysts’ expectations of $72.66 million. On average, equities analysts predict that Lantheus Holdings Inc. will post $0.53 earnings per share for the current fiscal year.
Lantheus Holdings, Inc develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.